Phase 2 AZA-PD Trial Results: Azathioprine's Promise in Slowing Parkinson's Progression

Overview of the AZA-PD Trial Design and Objectives

The AZA-PD trial, formally known as Azathioprine for the treatment of early Parkinson's disease, represents a significant effort in neurodegenerative research conducted at the University of Cambridge's Parkinson's Disease Research Clinic. This phase 2, randomised, double-blind, placebo-controlled proof-of-concept study enrolled 66 participants aged 50-80 years who were within three years of their Parkinson's disease (PD) diagnosis, adhering to the UK Parkinson's Disease Society Brain Bank Diagnostic Criteria. Participants were stratified based on a clinical prognostic score (CPS) to balance risk levels and randomly assigned 1:1 to receive either oral azathioprine at 2 mg/kg daily or a matched placebo for 12 months.

The primary objective was to assess whether peripheral immunosuppression could slow PD progression, specifically targeting the change in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) gait-axial score in the off-levodopa state at 12 months. This score evaluates posture, balance, gait freezing, and speech, areas often indicative of faster progression in early PD. Secondary outcomes included broader MDS-UPDRS subscales, Hoehn and Yahr staging, levodopa equivalent daily dose (LEDD), cognitive assessments like the Addenbrooke's Cognitive Examination-III (ACE-III), and quality-of-life measures such as the Parkinson's Disease Questionnaire (PDQ-39) and Non-Motor Symptoms Scale (NMSS). Exploratory endpoints encompassed immune biomarkers in blood and cerebrospinal fluid (CSF), as well as positron emission tomography (PET) imaging with [11C]PK11195 to measure microglial activation.

Funded by Cure Parkinson's and supported by the NIHR Cambridge Biomedical Research Centre, the trial underscores the collaborative role of UK academic institutions in advancing clinical neuroscience. Recruitment occurred between May 2021 and July 2022, with results published in January 2026 in The Lancet Neurology, marking a milestone in immune-targeted therapies for PD.

Defining Azathioprine and Its Mechanism in Parkinson's Context

Azathioprine, an immunosuppressive medication commonly used in organ transplantation and autoimmune conditions like rheumatoid arthritis, works by inhibiting purine synthesis, thereby reducing the proliferation of T and B lymphocytes. In the context of Parkinson's disease—a progressive neurodegenerative disorder characterised by alpha-synuclein aggregation, dopaminergic neuron loss in the substantia nigra, and neuroinflammation—it targets peripheral immune activation believed to exacerbate central pathology.

Emerging evidence suggests that PD involves dysregulated immunity, with elevated pro-inflammatory cytokines, activated microglia, and peripheral lymphocyte infiltration contributing to disease spread. Unlike dopamine-replacement therapies that manage symptoms, azathioprine aims for disease modification by dampening this immune response without crossing the blood-brain barrier significantly, potentially minimising CNS-specific risks. Dosing began at 1 mg/kg, titrated to 2 mg/kg after four weeks if tolerated, monitored closely for myelosuppression and infections.

This approach builds on preclinical data and observational studies linking immune profiles to PD prognosis, positioning AZA-PD as a pioneering test of broad immunosuppression in early, prognostically stratified PD patients.

Primary Outcome: No Significant Slowing of Gait-Axial Progression

The trial's primary endpoint revealed no statistically significant difference in MDS-UPDRS gait-axial score progression. At 12 months, the azathioprine group showed a mean change of 0.54 points (SD 2.43), compared to 0.13 points (SD 2.09) in the placebo group, with an effect size of 0.438 (95% CI -0.694 to 1.57; p=0.78). This minimal overall progression across arms highlights the challenge of detecting change in early PD over one year using this sensitive marker.

While disappointing for azathioprine as a standalone progression-slowing agent, the result provides a robust baseline for future studies, emphasising the need for longer durations or more responsive endpoints in low-progression cohorts.

Exploratory Clinical Benefits: Symptom Improvements and Subgroups

Despite the primary miss, exploratory analyses uncovered promising signals. The MDS-UPDRS Part II score (motor experiences of daily living, assessing tasks like dressing and eating) improved significantly in the azathioprine group at 6 months (-1.55 points; 95% CI -3.08 to -0.016; p=0.048) and 12 months (-1.62; 95% CI -3.20 to -0.034; p=0.045), suggesting better daily function.

Strikingly, subgroup effects were pronounced in females (35% of cohort), who exhibited clinically meaningful improvements exceeding minimal important differences: MDS-UPDRS Part II (-3.89; p=0.004), total score, PDQ-39, and NMSS. High-CPS (faster-progressing) patients showed cognitive gains on ACE-III (+3.33; p=0.010). These findings advocate for sex-stratified trial designs, reflecting sex differences in PD immunity and progression.

• MDS-UPDRS Part I (non-motor daily living): Female benefit p=0.004
• PDQ-39 quality of life: Reduced deterioration in females
• NMSS non-motor burden: Significant alleviation in female subgroup

Such nuances highlight personalised medicine's potential in PD therapeutics.

Biomarker Evidence: Immune Modulation Confirmed

Azathioprine robustly altered immune profiles, validating its peripheral action. Blood analyses showed lymphocyte reductions (e.g., CD3+ T cells), monocyte decreases (females), and neutrophil shifts. CSF immunophenotyping (via lumbar puncture) confirmed central effects: CD3+ cells reduced by -143.7/µL (95% CI -276.9 to -10.5; p=0.018), alongside CD4+, CD8+, and NK cells.

PET imaging with [11C]PK11195 indicated less microglial activation progression in azathioprine-treated brains, contrasting placebo's widespread increases in temporal and occipital regions. These data provide the first human evidence that peripheral immunosuppression impacts CNS inflammation in PD, opening avenues for biomarker-driven trials.

Photo by Rollz International on Unsplash

Safety Profile: Well-Tolerated in PD Population

Safety was comparable between arms, with 159 adverse events in azathioprine vs 156 placebo. Common issues included infections (61% vs 76%) and gastrointestinal disorders (58% vs 50%), typical for immunosuppressants. Serious adverse events occurred in 24% (8/33) azathioprine vs 12% (4/34) placebo, including two possibly drug-related (pancreatitis, pneumonia). No excess mortality or opportunistic infections, affirming feasibility for PD use.

This tolerability supports advancing selective immunosuppressants, with vigilant monitoring.

Implications for UK Higher Education and Neuroscience Research

Led by Dr Caroline Williams-Gray and team at the University of Cambridge, AZA-PD exemplifies UK leadership in PD research. Collaborations with Cambridge Clinical Trials Unit and Wolfson Brain Imaging Centre demonstrate interdisciplinary excellence, fostering PhD and postdoc opportunities in clinical neuroscience.

The trial's integration of PET, CSF analysis, and AI-assisted imaging analysis highlights advanced methodologies in university settings. For aspiring researchers, it signals growing demand for expertise in neuroimmunology, trial design, and biomarker development. Institutions like Cambridge continue to attract funding from NIHR and charities like Cure Parkinson's, driving innovation.

Explore research jobs or postdoc positions in neurology to contribute to such breakthroughs. Career advice on crafting academic CVs is available at how to write a winning academic CV.

Stakeholder Perspectives and Broader Context

Dr Williams-Gray noted the trial's encouragement for immune-targeting, while Dr Julia Greenland emphasised participant contributions. Cure Parkinson's hailed it as the first demonstration of immunosuppression improving symptoms in subsets. Patient advocates stress cautious optimism, given no primary efficacy.

In the UK, where PD affects 145,000 people (Parkinson's UK data), with 10,000 new diagnoses yearly, such research addresses unmet needs beyond levodopa. It aligns with national strategies like the 2022 UK Parkinson's Mission for Excellence.

Challenges, Limitations, and Lessons Learned

Limitations include single-site design, modest sample (powered pragmatically), short duration (minimal gait progression), and exploratory post-hoc analyses prone to multiplicity. Low female representation may underpower subgroups. PET's restrictiveness limits inflammation assessment.

• Need for larger, multi-centre phase 3 trials
• Sex-balanced recruitment and stratification
• Longer follow-up with composite progression endpoints
• Specific immune pathway targeting (e.g., JAK inhibitors)

These inform optimised designs, enhancing UK trial infrastructure.

Future Outlook: Paving the Way for Immunotherapies

AZA-PD validates immunosuppression's viability, spurring trials of targeted agents like anti-IL-6 or alpha-synuclein antibodies. Integration with genetics (e.g., GBA variants) and AI for patient selection promises precision. UK hubs like Cambridge position researchers at the forefront.

For professionals, opportunities abound in research assistant jobs and clinical research jobs.

Photo by Rollz International on Unsplash

Actionable Insights for Researchers and Clinicians

Prioritise biomarkers for trial enrichment; consider female-specific cohorts. Engage with higher ed career advice for advancing in this field.